HLX02 (trastuzumab biosimilar)
GPTKB entity
Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
biosimilar |
| gptkbp:approvedBy |
gptkb:China
gptkb:European_Union 2020 |
| gptkbp:ATCCode |
L01XC03
|
| gptkbp:biosimilar |
gptkb:trastuzumab
|
| gptkbp:developedBy |
gptkb:Shanghai_Henlius_Biotech
|
| https://www.w3.org/2000/01/rdf-schema#label |
HLX02 (trastuzumab biosimilar)
|
| gptkbp:indication |
gptkb:HER2-positive_breast_cancer
HER2-positive metastatic gastric cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:HER2/neu_receptor
|
| gptkbp:marketedAs |
Zercepac
|
| gptkbp:mechanismOfAction |
HER2 receptor antagonist
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:bfsParent |
gptkb:Shanghai_Henlius_Biotech
|
| gptkbp:bfsLayer |
7
|